Syndax Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 184
- Market Cap
- $1.7B
- Introduction
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
Clinical Trials
32
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
Phase 1 Study of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with AML Harboring Alterations in KMT2A/MLL, NPM1, or NUP98 Genes
- Conditions
- Acute Myeloid Leukemias
- Interventions
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Syndax Pharmaceuticals Inc.
- Target Recruit Count
- 22
- Registration Number
- 2024-514531-18-00
- Locations
- 🇳🇱
Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
🇳🇱Universitair Medisch Centrum Groningen, Groningen, Netherlands
🇳🇱Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam, Netherlands
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 135
- Registration Number
- NCT06132256
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺Sunshine Coast University Hospital, Birtinya, Queensland, Australia
🇦🇺Wallace Street Specialist Centre, Brisbane, Queensland, Australia
Expanded Access Program for Revumenib
- Conditions
- Relapsed/Refractory Acute Leukemia
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Syndax Pharmaceuticals
- Registration Number
- NCT05918913
- Locations
- 🇺🇸
UCLA, UCLA RRMC, Drug Information Center, Department of Pharmaceutical Services Drug Supply Shipment, Los Angeles, California, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
🇺🇸Alabama Center for Childhood Cancer And Blood Disorders, Children's of Alabama, Birmingham, Alabama, United States
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
- Conditions
- Colorectal CancerSolid Tumors
- Interventions
- Drug: Chemotherapy
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT05731947
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, Manhattan, New York, United States
Study of Radiolabeled Revumenib in Adults With Acute Leukemia
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT05406817
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as New R&D Head and Chief Medical Officer
Dr. Nicholas Botwood joins Syndax Pharmaceuticals from Bristol Myers Squibb, bringing 25 years of oncology drug development and commercialization experience to accelerate the company's cancer therapy pipeline.
Kura Oncology's Menin Inhibitor Ziftomenib Shows Promise in Mid-Stage Cancer Trial
Kura Oncology and Kyowa Kirin report positive results from their Phase 2 clinical trial evaluating ziftomenib, a novel menin inhibitor for cancer treatment.
Syndax Highlights FDA-Approved Therapies and Anticipated Milestones at J.P. Morgan Healthcare Conference
Syndax launched Revuforj (revumenib) for relapsed/refractory acute leukemia with KMT2A translocation, receiving NCCN guideline inclusion for AML and ALL.
Syndax's Revuforj Approved for Leukemia, Biosion Inks $940M Antibody Deal with Aclaris
• Syndax Pharmaceuticals' Revuforj (revumenib) received FDA approval as the first menin inhibitor for relapsed or refractory acute leukemia with specific genetic translocations. • Biosion granted Aclaris Therapeutics exclusive global rights to develop two antibodies, including BSI-045B (anti-TSLP) and BSI-502 (bispecific TSLP/IL4R), for up to $940 million. • Novartis expanded its radiopharma portfolio, licensing a somatostatin receptor 2 radiotherapeutic candidate from Ratio Therapeutics for cancer, potentially worth $745 million plus royalties.
Syndax's Revuforj (revumenib) Receives FDA Approval for KM2A-Rearranged Leukemia
Syndax Pharmaceuticals' Revuforj (revumenib) has gained FDA approval for treating adult and pediatric patients with relapsed or refractory KM2A-rearranged acute myeloid leukemia (AML).
FDA Approves Revuforj (revumenib) as First Menin Inhibitor for KMT2A-Rearranged Leukemia
The FDA has approved Revuforj (revumenib) as the first and only menin inhibitor for relapsed or refractory acute leukemia with KMT2A translocation in adults and children.
FDA Approves Syndax's Revuforj (axatilimab) as First Menin Inhibitor for Relapsed/Refractory AML
The FDA has granted accelerated approval to Revuforj (axatilimab), a first-in-class menin inhibitor, for adult patients with relapsed or refractory acute myeloid leukemia (AML).
FDA Approves Revuforj (axatilimab) for Relapsed or Refractory Chronic Graft-versus-Host Disease
The FDA has granted approval to Revuforj (axatilimab) for the treatment of adult and pediatric patients 12 years and older with relapsed or refractory chronic graft-versus-host disease (cGVHD) after failure of one or two prior lines of systemic therapy.
FDA Approves Syndax's Revuforj, a First-in-Class Menin Inhibitor for Acute Leukemia
The FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for adults and children with relapsed or refractory acute leukemia with KMT2A rearrangement.
FDA Approves Revumenib for Relapsed or Refractory KMT2A-Rearranged Acute Leukemia
The FDA has approved revumenib (Revuforj) for adult and pediatric patients (≥1 year) with relapsed or refractory acute leukemia harboring a KMT2A translocation.